Migraine Care in the Telehealth Era: Pandemic-Driven Shifts and Future Models

The COVID-19 pandemic didn't just disrupt healthcare—it forced a decade's worth of telemedicine adoption into months. For migraine, a condition defined by episodic disability, communication-heavy visits, and high patient engagement, the shift revealed both promise and peril.

Key Shifts During the Pandemic

Virtual Visits Became Standard

  • Enabled continuity for stable patients on established regimens.
  • Eliminated travel burden during attacks (light/sound sensitivity, nausea).
  • Reduced no-show rates; increased access for rural/underserved patients.

Loss of Physical Examination

  • No fundoscopy (papilledema screening — critical for IIH/secondary headache).
  • No neurological exam (cranial nerves, strength, reflexes, gait).
  • No blood pressure measurement (hypertension mimic, medication side effect).
  • No trigger point palpation (cervicogenic contributors).

Delayed New Diagnoses

  • New-onset headache patients faced months-long waits for in-person slots.
  • Secondary causes (mass lesions, vascular, infectious) risked delayed detection.
  • Red flags (thunderclap, positional, exertional, new focal signs) harder to triage virtually.

Mental Health Surge Required Integrated Care

  • Anxiety/depression exacerbations skyrocketed — bidirectional with migraine.
  • CBT, mindfulness, ACT delivered virtually — effective but access uneven.
  • Medication management complexity increased (polypharmacy, interactions).

Medication Access Disruptions

  • Supply chain issues (especially generics, injectables).
  • Prior authorization delays compounded by staffing shortages.
  • CGRP mAb injections (Aimovig, Emgality, Ajovy, Vyepti) — home administration protocols developed.

Communication Challenges

  • Loss of non-verbal cues: pain behaviors, affect, cognitive effort.
  • "Web-side manner" became a clinical skill: deliberate eye contact, verbal check-ins, screen-sharing diaries/apps.

Positive Outcomes: What Worked

  • Patient empowerment: Increased self-tracking (apps: Migraine Buddy, N1-Headache, Curelator), treatment literacy, shared decision-making.
  • Expanded access: Rural, disabled, caregiving, transportation-barrier patients gained specialist access.
  • Hybrid models emerging: Telehealth for follow-ups, medication checks, CBT; in-person for new evals, procedures (Botox, nerve blocks, infusions), red-flag workups.

Research Impact

  • Clinical trials paused; recruitment halted.
  • Decentralized trial designs accelerated: e-consent, e-diaries, home drug delivery, remote monitoring — now informing post-pandemic trial methodology.

The Future: Defining the Optimal Balance

Guidelines for tele-neurology are evolving (AAN, AHS). Key questions:

  • Which visit types require in-person? (New patient, procedural, red flags, complex comorbidity.)
  • How to standardize virtual neurological exam components?
  • Reimbursement parity sustainability?
  • Digital divide mitigation (broadband, device access, digital literacy)?
  • Quality metrics for virtual headache care?

The pandemic didn't invent telehealth for migraine—it proved its viability at scale. The task now: codify what works, mandate what's essential in-person, and ensure equity. The hybrid future isn't a compromise—it's an expansion of the therapeutic reach.

Migraine - Related Articles